| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
|
US8791270 (Pediatric) | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) | |
| US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
Bendeka is owned by Eagle Pharms.
Bendeka contains Bendamustine Hydrochloride.
Bendeka has a total of 18 drug patents out of which 0 drug patents have expired.
Bendeka was authorised for market use on 07 December, 2015.
Bendeka is available in solution;iv (infusion) dosage forms.
Bendeka can be used as for the treatment of patients with chronic lymphocytic leukemia, for use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma, for the treatment of patients with indolent b-cell non-hodgkin lymphoma, for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma.
The generics of Bendeka are possible to be released after 15 March, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients w...
Dosage: SOLUTION;IV (INFUSION)
BENDEKA family patents
